紫杉醇联合调强放疗对中晚期宫颈癌的疗效及血清OPN、MMP-9表达水平的影响

doi:10.3969/j.issn.1671-7171.2022.06.022

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1143 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of paclitaxel combined with intensity modulated radiation therapy and its effects on the expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in patients with advanced cervical cancer. 【Methods】A total of 118 patients with advanced cervical cancer in our hospital,were divided into the control group and the observation group according to the treatment plan. The control group of 58 cases were treated with intensity modulated radiotherapy + cisplatin; the study group of 60 cases were treated with paclitaxel on the basis of the control group. The short-term efficacy,long-term efficacy and adverse reactions were compared between the two groups,and the expression levels of serum OPN and MMP-9 were detected and compared as well. 【Results】The short-term effective rate of the observation group was 91.67% and that of the control group was 84.48%. However,there was no significant difference between the two groups (P>0.05). After treatment,the expression levels of serum OPN and MMP-9 in the two groups were lower than those before treatment (P<0.05); And the expression levels of serum OPN and MMP-9 in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of recent adverse reactions between the two groups (P>0.05). The 3-year cumulative survival rate of the observation group was 73.33% (44/60),which was significantly higher than that of the control group 51.72% (30/58),and the Log Rank test results indicated that the overall survival curves of the two groups were significantly different (P<0.05). 【Conclusion】Paclitaxel combined with intensity modulated radiation therapy is effective in the treatment of advanced cervical cancer. It can down-regulate the expression of serum OPN and MMP-9,improve the long-term survival rate,and the safety is acceptable.

Key words： Uterine Cervical Neoplasms/RT Paclitaxel/TU Metalloproteases/BL Osteopontin/BL

Received: 06 December 2021

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jin-tao
	MA Xian-ping

Cite this article:

ZHANG Jin-tao,MA Xian-ping. Efficacy of Paclitaxel Combined with Intensity Modulated Radiation Therapy on Advanced Cervical Cancer and Expression of Serum OPN and MMP-9[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 881-884.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.06.022 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I6/881

[1] 张韶凯,赵方辉,乔友林.中国宫颈癌防治研究20年历程与成就[J].中华流行病学杂志,2020,41(6):809-812.
[2] 王宇,宋淑芳,刘凤.我国宫颈癌流行病学特征和发病高危因素的研究进展[J].中国妇幼保健,2019,34(5):1206-1208.
[3] 韦蒙专,陈绍俊,黄海欣.中晚期宫颈癌综合治疗模式的研究现状和进展[J].中国肿瘤,2019,28(6):456-460.
[4] 朱锦贤,郭毅,邹元梅.三维适形放射治疗与调强放射治疗联合同步化疗治疗局部晚期宫颈癌患者的临床疗效和安全性比较[J].广西医学,2019,41(24):3122-3126.
[5] 向安玲,庄瑞春,彭玲.紫杉醇联合顺铂新辅助化疗对晚期宫颈癌患者淋巴结转移率及远期预后的影响[J].河北医学,2019,25(2):219-223.
[6] PECORELLI S,ZIGLIANI L,ODICINO F.Revised FIGO staging for carcinoma of the vulva,cervix,and endometrium.[J].Int J Gynecol Obstet,2009,105(2):103-104.
[7] 中华人民共和国国家卫生和计划生育委员会.宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(8):40-49.
[8] SCHWARTZ LH,BOGAERTS J,FORD R,et al.Evaluation of lymph nodes with RECIST 1.1[J].Eur J Cancer,2009,45(2):261-267.
[9] 戚瑞虹,桂定清,张力忆.自适应调强与单程调强放射治疗局部晚期宫颈癌的临床疗效及毒副反应对比分析[J].西部医学,2019,31(3):428-434.
[10] 卢家希,陈晓品.紫杉醇联合卡铂化疗同期调强适形放疗对老年晚期宫颈癌患者疗效观察及对患者生活质量和免疫功能影响[J].重庆医科大学学报,2018,43(2):240-244.
[11] 朱佳浩,顾科.宫颈癌放射敏感性预测在精准治疗中的研究现状及进展[J].中国临床实用医学,2018,9(6):74-76.
[12] 贾利平,周小飞,王发辉,等.骨桥蛋白在宫颈癌中的表达及其对化疗效果的影响[J].临床和实验医学杂志,2018,17(7):763-766.
[13] 潘冰,陈慧,郑炜智,等.宫颈癌患者临床病理特点及P16、SDF-1、MMP-9和VEGF-C的表达[J].中国妇幼保健,2018,33(22):5105-5107.
[14] 陈建华,叶丽君,喻长法,等.骨桥蛋白、血管内皮生长因子和基质金属蛋白酶-9在宫颈癌患者中的表达及意义[J].中国卫生检验杂志,2020,30(18):2215-2217.